Univest
Univest
  • Markets

3 Respiratory Drugs Maker, IT Services Company and Transmission Towers Maker Stocks With a Strong Future Roadmap: Cipla, Tech Mahindra and Karamtara Engineering

  • November 17, 2026
  • Posted by: Harsh Piplani
  • Category: Best Stocks
No Comments
3 Respiratory Drugs Maker, IT Services Company and Transmission Towers Maker Stocks With a Strong Future Roadmap: Cipla, Tech Mahindra and Karamtara Engineering

Cipla, Tech Mahindra and Karamtara Engineering: ROE of 11.3% to 18.8% and FY22 to FY26 revenue CAGR of 5.6% to 36.4%. Prices as of 16 Nov 2026.

Quick Answer

The three inhaler, IT service and tower stocks to watch are Cipla, Tech Mahindra and Karamtara Engineering. Their return on equity ranges from 11.3% to 18.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 36.4%. Karamtara Engineering leads on both return on equity at 18.8% and revenue growth at 36.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Inhaler, IT service and tower stocks let investors follow companies that serve a growing part of the Indian economy. Cipla, Tech Mahindra and Karamtara Engineering cover a respiratory drugs maker, an IT services company and a transmission towers maker.

This list covers three inhaler, IT service and tower stocks with complete current figures: Cipla, Tech Mahindra and Karamtara Engineering. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Inhaler, IT Service and Tower Stocks?
  • Inhaler, IT Service and Tower Stocks at a Glance
  • Why Do Inhaler, IT Service and Tower Stocks Have a Strong Roadmap in India?
  • Why Cipla Features Among These Inhaler, IT Service and Tower Stocks
  • Why Tech Mahindra Features Among These Inhaler, IT Service and Tower Stocks
  • Why Karamtara Engineering Features Among These Inhaler, IT Service and Tower Stocks
  • Cipla vs Tech Mahindra vs Karamtara Engineering on Key Financials
  • Key Risks to Check Before Investing in Inhaler, IT Service and Tower Stocks
  • Final Thoughts on Inhaler, IT Service and Tower Stocks
    • What are inhaler, IT service and tower stocks?
    • Which inhaler, IT service and tower stocks are covered in this list?
    • Why do inhaler, IT service and tower stocks have a strong future roadmap in India?
    • How has Cipla performed financially?
    • How has Tech Mahindra performed financially?
    • How has Karamtara Engineering performed financially?
    • What risks should investors check before buying inhaler, IT service and tower stocks?
    • Is this list of inhaler, IT service and tower stocks investment advice?

What Are Inhaler, IT Service and Tower Stocks?

Inhaler, IT service and tower stocks are listed companies that make generic and respiratory medicines for India and global markets, provide software and IT services to global clients, and make steel towers and structures for power transmission lines. Their earnings depend on medicine demand, client technology budgets and power grid spending.

Inhaler, IT Service and Tower Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Cipla 1,394.5 107,528 32.0 36.0 11.3 0.02
Tech Mahindra 1,776.4 175,398 31.5 17.6 18.6 0.07
Karamtara Engineering 369.95 11,949 52.2 43.9 18.8 0.91

On valuation, Cipla trades at a P/E below the industry P/E, while Tech Mahindra and Karamtara Engineering trade above it, which reflects the growth the market already expects. Readers comparing inhaler, IT service and tower stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Inhaler, IT Service and Tower Stocks Have a Strong Roadmap in India?

Inhaler, IT service and tower stocks have a strong roadmap in India because steady demand for respiratory care, rising client spending on digital projects and large grid expansion plans keep widening the market for these companies.

  • Respiratory medicines. Patients need reliable inhalers and tablets.
  • IT services. Clients buy digital and cloud projects.
  • Transmission towers. Grids need new high voltage lines.

Why Cipla Features Among These Inhaler, IT Service and Tower Stocks

Among the inhaler, IT service and tower stocks on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.

In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

Why Tech Mahindra Features Among These Inhaler, IT Service and Tower Stocks

Among the respiratory drug, software exporter and pylon shares on this list, Tech Mahindra is a Mahindra Group technology services company that provides digital, network and enterprise services to clients in telecom, manufacturing, banking and other industries worldwide.

Revenue rose from Rs 45,758 crore in FY22 to Rs 56,847 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 2,397 crore in FY24 to Rs 4,806 crore in FY26, which works out to a compound annual growth rate of 41.6%.

The company has a return on equity of 18.6%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 175,398 crore. The stock trades at a P/E of 31.5, above the industry P/E of 17.6.

Roadmap: The company is investing in artificial intelligence, cloud and 5G related services and deepening ties with large clients. Large deal wins in telecom and enterprise work support its pipeline.

What to watch: Track large deal wins, margin improvement and demand from telecom and enterprise clients.

Why Karamtara Engineering Features Among These Inhaler, IT Service and Tower Stocks

Among the three companies on this list, Karamtara Engineering makes transmission line towers, monopoles and structures for power utilities, and also supplies solar mounting structures.

The company has a return on equity of 18.8%, a debt to equity ratio of 0.91 and a market capitalisation of Rs 11,949 crore. The stock trades at a P/E of 52.2, above the industry P/E of 43.9.

Revenue rose from Rs 1,247 crore in FY22 to Rs 4,316 crore in FY26, a compound annual growth rate of 36.4%. Net profit grew from Rs 103 crore in FY24 to Rs 229 crore in FY26, which works out to a compound annual growth rate of 49.3%.

Roadmap: Large transmission corridors and renewable energy connections create sustained demand for towers and structures. The company is widening its capacity and its customer base, which includes state utilities and power grid developers.

What to watch: Keep an eye on order execution timelines and steel price movements.

Cipla vs Tech Mahindra vs Karamtara Engineering on Key Financials

The table below sets the three inhaler, IT service and tower stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Cipla 22,044 29,045 7.1% 3,870 13.3%
Tech Mahindra 45,758 56,847 5.6% 4,806 8.5%
Karamtara Engineering 1,247 4,316 36.4% 229 5.3%

Karamtara Engineering posts the highest return on equity in this group at 18.8%. Tech Mahindra has the largest FY26 revenue at Rs 56,847 crore, and Karamtara Engineering shows the fastest revenue growth with a 36.4% compound annual rate.

Key Risks to Check Before Investing in Inhaler, IT Service and Tower Stocks

Every theme carries risks that deserve a check before any decision. For these inhaler, IT service and tower stocks, the main points are:

  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Client spending. Technology budgets can vary with global conditions.
  • Order timing. Project awards can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter inhaler, IT service and tower stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Inhaler, IT Service and Tower Stocks

Inhaler, IT service and tower stocks reward investors who follow demand trends, order books and margins together. Cipla, Tech Mahindra and Karamtara Engineering each have a clear plan to grow. Based on the 16 November 2026 close, Cipla trades at Rs 1,394.5, Tech Mahindra at Rs 1,776.4 and Karamtara Engineering at Rs 369.95.

Download the Univest iOS App or Univest Android App to track inhaler, IT service and tower stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are inhaler, IT service and tower stocks?

Ans. Inhaler, IT service and tower stocks are listed companies that make generic and respiratory medicines for India and global markets, provide software and IT services to global clients, and make steel towers and structures for power transmission lines. Their earnings depend on medicine demand, client technology budgets and power grid spending. This list looks at three of them, Cipla, Tech Mahindra and Karamtara Engineering, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which inhaler, IT service and tower stocks are covered in this list?

Ans. This list covers Cipla, Tech Mahindra and Karamtara Engineering. Based on the 16 November 2026 close, Cipla traded at Rs 1,394.5, Tech Mahindra at Rs 1,776.4 and Karamtara Engineering at Rs 369.95. Their return on equity ranges from 11.3% to 18.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 36.4%.

Why do inhaler, IT service and tower stocks have a strong future roadmap in India?

Ans. Inhaler, IT service and tower stocks have a strong roadmap in India because steady demand for respiratory care, rising client spending on digital projects and large grid expansion plans keep widening the market for these companies. The main drivers are as follows. Respiratory medicines. Patients need reliable inhalers and tablets. IT services. Clients buy digital and cloud projects. Transmission towers. Grids need new high voltage lines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

How has Tech Mahindra performed financially?

Ans. Revenue rose from Rs 45,758 crore in FY22 to Rs 56,847 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 2,397 crore in FY24 to Rs 4,806 crore in FY26, which works out to a compound annual growth rate of 41.6%. The company has a return on equity of 18.6%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 175,398 crore. The stock trades at a P/E of 31.5, above the industry P/E of 17.6. Looking ahead, the company is investing in artificial intelligence, cloud and 5G related services and deepening ties with large clients. Large deal wins in telecom and enterprise work support its pipeline.

How has Karamtara Engineering performed financially?

Ans. Revenue rose from Rs 1,247 crore in FY22 to Rs 4,316 crore in FY26, a compound annual growth rate of 36.4%. Net profit grew from Rs 103 crore in FY24 to Rs 229 crore in FY26, which works out to a compound annual growth rate of 49.3%. The company has a return on equity of 18.8%, a debt to equity ratio of 0.91 and a market capitalisation of Rs 11,949 crore. The stock trades at a P/E of 52.2, above the industry P/E of 43.9. Looking ahead, large transmission corridors and renewable energy connections create sustained demand for towers and structures. The company is widening its capacity and its customer base, which includes state utilities and power grid developers.

What risks should investors check before buying inhaler, IT service and tower stocks?

Ans. Investors should check a few risks before buying inhaler, IT service and tower stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of inhaler, IT service and tower stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks Cipla generic medicines inhaler IT outsourcing and transmission tower stocks IT service and tower stocks Karamtara Engineering respiratory drug software exporter and pylon shares Tech Mahindra
Author: Harsh Piplani
I am Harsh Piplani, an Assistant Content Manager with over 5 years of experience in crafting impactful, result-driven content. I hold a B.Com (Hons) degree and have worked across diverse industries, including education, fintech, healthcare, jewellery, and more. I specialise in content strategy, SEO, and optimisation, ensuring that every piece I create is not just well-written but also well-ranked. I believe content should do more than fill space so as to drive traffic, build authority, and support business growth. I enjoy turning complex ideas into clear, engaging narratives, and, as I like to say, I know how to spin words like a web to influence, structured, strategic, and impossible to ignore. For me, great content sits at the intersection of creativity and performance.

Leave a Reply Cancel reply